Novel Beta-Agonists, Process for Their Preparation and Their Use as Medicaments
申请人:Walter Rainer
公开号:US20080300290A1
公开(公告)日:2008-12-04
Compounds of general formula (I)
which are selective beta-3-agonists and useful for the treatment of obesity and type II diabetes. Exemplary compounds are:
[4-(1-3-[2-(3-phenylsulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazol-4-yl)-phenyl]-acetic acid and
methyl [4-(1-3-[2-(3-phenylsulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazol-4-yl)-phenyl]-acetate.
Urea Compounds and Their Use as FAAH Enzyme Inhibitors
申请人:BIAL-PORTELA & Cª, S.A.
公开号:US20160166560A1
公开(公告)日:2016-06-16
A compound having Formula I:
wherein: R1 is selected from hydrogen, halogen, hydroxyl and C
1-4
alkoxy; R2 is selected from hydrogen, halogen, hydroxyl and C
1-4
alkoxy; R3 is C
1-4
alkyl; R4 is aryl which is substituted with a group selected from OSO
2
NH
2
, NHCONH
2
, NHSO
2
NH
2
, NHSO
2
C
1-4
alkyl and CONH
2
; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; provided that the compound is not N-(1-benzylpiperidin-4-yl)-N-methyl-4-(4-(sulfamoylamino)phenyl)-1H-imidazole-1-carboxamide or N-(1-benzylpiperidin-4-yl)-N-methyl-4-(3-(methyl sulfonamido)phenyl)-1H-imidazole-1-carboxamide. The compound may be used as an inhibitor of fatty acid amide hydrolase.